Study |
Type of data |
Exposure measurement |
Outcome assessment |
Adjustment |
Huybrechts (Controls unexposed, NOS), 2023
|
population based cohort retrospective
|
Exposure to atypical and typical antipsychotics was defined based on filling 1 or more prescriptions of the respective drug class during the first trimester, the period for organogenesis. => Prescription databases.
|
Nordic Countries: outcomes are defined based on data from the Medical Birth, Malformation and/or Patient Registers from the date of birth to one year after birth. USA: claims in infant record between birth and birth more 90 days and/or in the maternal record, using both in- and out-patient data.
|
Propensity score approach to control for potential confounders: demographic factors (maternal age..), treatment indications/mental disorders, maternal/obstetrical conditions (hypertension, diabetes, ...), lifestyle behaviors (tobacco, alcohol, ...), other medications, and health care utilization metrics. Exclusion of pregnancies exposed to a known teratogenic medication. Singleton births only.
|
Huybrechts (Controls unexposed, sick), 2023
|
population based cohort retrospective
|
Exposure to atypical and typical antipsychotics was defined based on filling 1 or more prescriptions of the respective drug class during the first trimester, the period for organogenesis. => Prescription databases.
|
Nordic Countries: outcomes are defined based on data from the Medical Birth, Malformation and/or Patient Registers from the date of birth to one year after birth. USA: claims in infant record between birth and birth more 90 days and/or in the maternal record, using both in- and out-patient data.
|
Propensity score approach to control for potential confounders: demographic factors (maternal age..), treatment indications/mental disorders, maternal/obstetrical conditions (hypertension, diabetes, ...), lifestyle behaviors (tobacco, alcohol, ...), other medications, and health care utilization metrics. Exclusion of pregnancies exposed to a known teratogenic medication. Singleton births only.
|
Kulkarni, 2024
|
prospective cohort
|
Pregnant women were interviewed and monitored by the research team. With consent, information was also sought from treating clinicians and medical records.
|
Pregnant women were interviewed and monitored by the research team. With consent, information was also sought from treating clinicians and medical records.
|
No adjustment. The confounding variables were analyzed using univariate models with just 1 explanatory variable at a time.
|
McKenna, 2005
|
prospective cohort
|
Exposure declared by women during exposure and data were achieved by sending each general practitioner a detailed questionnaire with questions regarding drug history.
|
This was achieved by sending each general practitioner a detailed questionnaire with questions regarding pregnancy outcome. Once the questionnaire was completed, permission was requested to receive a report from the physician primarily caring for the infant.
|
No adjustment/match for this exposed group.
|
Peng, 2013
|
prospective cohort
|
A detailed questionnaire completed by all enrolled pregnant women prior to delivery. Once the questionnaire was completed, permission was requested to receive a report from the physician and obstetrician.
|
The Bayley-III was administered by a psychologist who specialized in this scale and assessed neurodevelopment of children for the hospital. The psychologist was not a part of research team and was blinded during all neurobehavioral development assessments
|
No adjustment/match for this exposed group.
|
Reis (Control exposed to FGA), 2008
|
population based cohort retrospective
|
Maternal drug use in early pregnancy is recorded from interviews performed by the midwife at the first antenatal care visit, usually before the end of the first trimester.
|
3 national health registers: the Medical Birth Register, the Swedish Register of Congenital Malformations, and the Hospital Discharge Register
|
No adjustment for this exposed group.
|
Reis (Unexposed control, NOS), 2008
|
population based cohort retrospective
|
Maternal drug use in early pregnancy is recorded from interviews performed by the midwife at the first antenatal care visit, usually before the end of the first trimester
|
3 national health registers: the Medical Birth Register, the Swedish Register of Congenital Malformations, and the Hospital Discharge Register
|
No adjustment for this exposed group.
|